Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020:2116:781-789.
doi: 10.1007/978-1-0716-0294-2_46.

In Vitro Drug Efficacy Testing Against Trypanosoma brucei

Marcel Kaiser  1   2 , Pascal Mäser  3   4
Affiliations

In Vitro Drug Efficacy Testing Against Trypanosoma brucei

Marcel Kaiser et al. Methods Mol Biol. 2020.

Abstract

The recent endorsement of fexinidazole by the European Medicines Agency for the treatment of human African trypanosomiasis has demonstrated the high predictive value of cell-based assays for parasite chemotherapy. Here we describe three in vitro drug susceptibility tests with Trypanosoma brucei that have served as the basis for the identification of fexinidazole as a promising lead: (1) a standard assay with end-point measurement to determine drug efficacy; (2) a wash-out assay to test for reversibility and speed of drug action; (3) isothermal microcalorimetry for real-time measurement of onset of drug action and time to kill. Together, these assays allow to estimate pharmacodynamic parameters in vitro and to devise appropriate treatment regimens for subsequent in vivo experiments.

Keywords: African trypanosomes; Cell-based assay; Drug discovery; Drug sensitivity testing; Isothermal microcalorimetry; Parasite chemotherapy; Pharmacodynamics; Trypanosoma brucei.

PubMed Disclaimer

References

    1. Mäser P, Wittlin S, Rottmann M et al (2012) Antiparasitic agents: new drugs on the horizon. Curr Opin Pharmacol 12:562–566 - DOI - PubMed
    1. Mesu V, Kalonji WM, Bardonneau C et al (2018) Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet 391:144–154 - DOI - PubMed
    1. Torreele E, Bourdin Trunz B, Tweats D et al (2011) Fexinidazole—a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis 4:e923 - DOI
    1. Räz B, Iten M, Grether-Bühler Y et al (1997) The Alamar Blue assay to determine drug sensitivity of African trypanosomes in vitro. Acta Trop 68:139–147 - DOI - PubMed
    1. Kaiser M, Bray MA, Cal M et al (2011) Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. Antimicrob Agents Chemother 55:5602–5608 - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources